We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Amphastar Pharmaceuticals (AMPH) Could Be Positioned for a Surge
Read MoreHide Full Article
Amphastar Pharmaceuticals, Inc. (AMPH - Free Report) is a Generic Drug company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AMPH’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Amphastar Pharmaceuticals could be a solid choice for investors.
Current Quarter Estimates for AMPH
In the past 30 days, 1 estimate has gone higher for Amphastar Pharmaceuticals with no downward revisions in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 1 cent a share 30 days ago, to earnings of 8 cents today, making a considerable move.
Current Year Estimates for AMPH
Meanwhile, Amphastar Pharmaceuticals‘ current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to no downward revisions. The consensus estimate trend has also seen a boost for this time frame, increasing from 5 cents per share 30 days ago to 22 cents per share today, making a significant increase.
The stock has also started to move higher lately, adding 5.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Amphastar Pharmaceuticals (AMPH) Could Be Positioned for a Surge
Amphastar Pharmaceuticals, Inc. (AMPH - Free Report) is a Generic Drug company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AMPH’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Amphastar Pharmaceuticals could be a solid choice for investors.
Current Quarter Estimates for AMPH
In the past 30 days, 1 estimate has gone higher for Amphastar Pharmaceuticals with no downward revisions in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 1 cent a share 30 days ago, to earnings of 8 cents today, making a considerable move.
Current Year Estimates for AMPH
Meanwhile, Amphastar Pharmaceuticals‘ current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to no downward revisions. The consensus estimate trend has also seen a boost for this time frame, increasing from 5 cents per share 30 days ago to 22 cents per share today, making a significant increase.
AMPHASTAR PHARM Price and Consensus
AMPHASTAR PHARM Price and Consensus | AMPHASTAR PHARM Quote
Bottom Line
The stock has also started to move higher lately, adding 5.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>